Valuation
- Market cap
- —
- Revenue TTM
- $731,783,000
- Net income TTM
- $43,642,000
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 3.44%
- Debt to equity
- 1.33
Trading
- Volume
- 300
- Avg volume
- 116
- Day's range
- $12.53 – $13.35
- Shares out
- —
- Stochastic %K
- 82%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-...
Show more
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management. The company is involved in the development and sale of CBD-integrated pharmaceuticals and topical products. In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company was incorporated in 2018 and is headquartered in Calgary, Canada.
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
- Phone
- 403-777-1519
- Website
- https://innocanpharma.com
- Address
- 1015, 926 – 5 Avenue SW, Calgary, Canada
Latest news
No headlines yet.
